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A multicomponent nutrient bar promotes weight loss and
improves dyslipidemia and insulin resistance in the
overweight/obese: chronic inflammation blunts
these improvements
Joyce C. McCann,*,1 Mark K. Shigenaga,*,1 Michele L. Mietus-Snyder,*,† Ashutosh Lal,*
Jung H. Suh,* Ronald M. Krauss,* Ginny L. Gildengorin,* Alisa M. Goldrich,* Devan S. Block,*
Swapna V. Shenvi,* Tara H. McHugh,‡ Don A. Olson,‡ and Bruce N. Ames*
*Nutrition and Metabolism Center, Children’s Hospital Oakland Research Institute, Oakland, California,
USA; †Children’s National Medical Center, Washington, DC, USA; and ‡Processed Foods Research Unit,
U.S. Department of Agriculture-Agricultural Research Service-Western Regional Research Center,
Albany, California, USA
ABSTRACT This study determined if twice-daily con-
sumption of a nutrient-dense bar intended to fill gaps in
Western diets, without other dietary/lifestyle require-
ments, favorably shifted metabolic/anthropometric indi-
cators of dysregulation in a healthy direction. Three 8-wk
clinical trials in 43 healthy lean and overweight/obese
(OW/OB) adults, who served as their own controls, were
pooled for analysis. In less inflamed OW/OB [high-
sensitivity C-reactive protein (hsCRP) <1.5], statistically
significant decreases occurred in weight (21.1 6 0.5 kg),
waist circumference (23.1 6 1.4 cm), diastolic blood
pressure (24.16 1.6 mmHg), heart rate [HR;24.06 1.7
beatsperminute (bpm)], triglycerides (2726 38.2mg/dl),
insulin resistance (homeostatic model of insulin re-
sistance) (20.72 6 0.3), and insulin (22.8 6 1.3 mU/L);
an increase in HDL-2b (+3036 116 nM) and realignment
of LDL lipid subfractions toward a less atherogenic profile
[decreased small LDL IIIb (244 6 23.5 nM), LDL IIIa
(2996 43.7nM),andincreasedlargeLDLI(+66628.0nM)].
In the more inflamed OW/OB (hsCRP >1.5), inflam-
mation was reduced at 2 wk (20.66 mg/L), and HR at
8 wk (23.4 6 1.3 bpm). The large HDL subfraction
(10.5–14.5 nm) increased at 8 wk (+346 6 126 nM). Meta-
bolic improvements were also observed in lean participants.
Thus, favorable changes in measures of cardiovascular
health, insulin resistance, inflammation, and obesity were
initiated within 8 wk in the OW/OB by replacing defi-
ciencies in Western diets without requiring other die-
tary or lifestyle modifications; chronic inflammation
blunted most improvements.—McCann, J. C., Shigenaga,
M. K., Mietus-Snyder, M. L., Lal, A., Suh, J. H., Krauss,
R. M., Gildengorin, G. L., Goldrich, A. M., Block, D. S.,
Shenvi, S. V., McHugh, T. H., Olson, D. A., Ames, B. N. A
multicomponent nutrient bar promotes weight loss
and improves dyslipidemia and insulin resistance in
the overweight/obese: chronic inflammation blunts
these improvements. FASEB J. 29, 3287–3301 (2015).
www.fasebj.org
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OVERCONSUMPTION OF WESTERN DIETS HIGH in calories, sugar,
salt, and unhealthy fats, but low in micronutrients [many
essential vitamins and minerals (Vs/Ms) and v-3 fatty
acids], fiber, and plant polyphenolics (1–4), is a major
cause of the increasing prevalence of obesity worldwide
(5–7). Such diets directly contribute to the metabolic dys-
regulation that usually accompanies obesity (8–11) and is
alsopresent in;25%of lean individuals (12, 13).Metabolic
dysregulation includes chronic inflammation, insulin re-
sistance, dyslipidemia, and oxidative stress (14, 15). Several
metabolic abnormalities, together with visceral adiposity
and high blood pressure (BP), are collectively termed “the
metabolic syndrome” (11, 16). Various aspects ofmetabolic
dysregulation have been shown to be independent risk
factors for cardiovasculardisease(CVD)and type2diabetes,
and putative risk factors for the many other obesity-
associated diseases including cancer, autoimmune dis-
orders, asthma, andneurodegenerative conditions (17–22).
Because poor diets are a root cause of these health
problems, an obvious approach to the obesity epidemic
would be to improve dietary habits. However, changing
dietary patterns is difficult for many people to initiate and
sustain (23–25).
Abbreviations: aka, also known as; BMI, body mass index;
BP, blood pressure; bpm, beats per minute; CVD, cardiovas-
cular disease; DBP, diastolic blood pressure; DHA, docosa-
hexaenoic acid; HDL-L, large HDL subfraction; HDLPs, total
HDL subfractions; HOMA-IR, homeostatic model of insulin re-
sistance; HPMC, hydroxypropylmethylcellulose; HR, heart rate;
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We have developed, guided by 18 small clinical trials
conducted over the last 10 years, a low-calorie, fruit-based
bar fortified with micronutrients, fiber, and other dietary
components inadequate in a typical Western diet (26).
This approach was based on the hypothesis that metabolic
dysregulation common in the obese (with consequent in-
creased disease risk) is due in large part to what is missing
or inadequate inWestern diets, andmight be improved by
increasing intake of these food components.
In addition to the bar having practical application as
a nutritional supplement to attenuate the adverse meta-
bolic impact of obesity and hopefully encouraging transi-
tion to healthier eating habits, a major goal was to use the
nutrient mixture as a scientific tool to investigate mecha-
nismsbywhich individual dietary components in a complex
dietary mixture interact with each other and with human
metabolism. Because the composition of the bar is defined
and easily manipulated, deconstruction studies aimed at
understandingmechanisms are quite feasible, whereas this
type of mechanistic detective work would be virtually im-
possible to do in human trials with a complete diet.
A great deal of evidence points to the impact of dietary
deficiencies on metabolic health. For example, low intake
of fruits, vegetables, and fish by the great majority of the
population in the United States (1, 27), with consequent
inadequate intake of many essential V/Ms (28), results in
low V/M status, which is particularly apparent in obese
people (29–33). Triage theory (34–37) provides a mecha-
nistic rationale for why essential V/M inadequacies com-
mon in Western diets increase future chronic disease risk.
Research also links other dietary deficiencies common in
typicalWestern diets to increased risk for chronic disease or
metabolic dysregulation. Examples include low intake of
dietary fiber (38–40) and its fermentation products [short-
chain fatty acids (41, 42) and glutamine (43–45)], plant
polyphenolics (46–49) and v-3 fatty acids (50).
Throughout development of the nutrient mixture, for-
mulationmodifications to improvepalatability andefficacy
were guided by small clinical trials that examined effects
of formulation modifications on a range of clinical bio-
chemical andanthropometricmeasures [(51);unpublished
results]. A simple and economical experimental design was
used for these trials. Participants acted as their own control
subjects and were not asked to modify their existing diets
during the course of the trial, consistent with our hypothesis
that adding back inadequate dietary components would be
sufficient to result in positive change. For further discus-
sion on development of the nutrient bar, see our earlier
paper (51).
Background/rationale for the current report
Early clinical trials were of short duration (2 wk) and in-
cluded healthy, predominantly lean, or only slightly over-
weight adults. Our previous report (51) indicated that
twice-daily consumption of the nutrient bar for 2 wk
resulted in a striking increase inmost participants in HDL-
cholesterol (HDL-c), particularly the large HDL sub-
fraction [designated HDL-L or HDL-2b (10.5–14.5 nm)].
HDL-2b is generally considered to be associated with less
future CVD risk (52, 53) andmay reflect increased reverse
cholesterol transport (RCT), an antiatherogenic function
of HDL (54).
Subsequent trials included both 2 wk and 2 month time
points and approximately equal numbers of lean and
overweight/obese (OW/OB) adults. This report presents
results of 3 of these 2month trials usingbars of comparable
fiber and nutrient composition. The major goal of the
analysis was to test whether bar consumptionwithout other
lifestyle modifications could shift metabolic dysregulation
in the OW/OB toward a “leaner” profile, and to confirm,
and extend to 2 months, results of earlier 2 wk trials in
predominantly lean individuals (51). Plasma concen-
trations of standard clinicalmetabolic and anthropometric
measures, lipid protein subfractions, the adipokine adi-
ponectin (55), and the acute phase protein serum amyloid
A (SAA) (56) were quantified at baseline, and after 2 and
8 wk of twice-daily consumption of the nutrient bar.
MATERIALS AND METHODS
Composition of the nutrient bars
Thenutrientbarsused in this studywere similar to theprototypebar
described previously (51). Themajor difference in the bars utilized
in this study compared to the prototype bar (51) is the substitution
of half of the soluble fiber with hydroxypropylmethylcellulose
(HPMC), a highly viscous, nonfermentable soluble fiber (57).
Bars used in the 3 trials presented here were identical except in
amountsof somevitamins (vitaminsA,D3, andK1 and folate) and
some fruitswithhighpolyphenol (anthocyanin) content, though
these differences did not affect outcome distributions (see “Sta-
tistical analysis”). Each trial used adifferentbar.Nutrientprofiles
of the 3 bars are in Table 1.
Study cohort
A total of 43 generally healthy adults participated in $1 of 3
identical 2-month trials conducted over a period of 4 years. There
were 10 participants in 2 trials; 5 were in 3 trials. Each trial was
separated by .1 year. There were 2 participants excluded from
the analysis because their baseline fasting blood glucose was
.126 mg/dl, indicating diabetes. One participant was excluded
from analysis because high-sensitivity C-reactive protein (hsCRP)
values for all 3 time points were.10 mg/L, indicating probable
infection (60). There were 4 individual hsCRP data points .10
(in 4 participants) also excluded. All but one of these high values
were supportedbydocumentationofeither a coldor allergyat the
time of the clinical research center visit. Data points corre-
sponding to these 4 excluded values were also removed for all
non-hsCRP parameters analyzed. A single outlier baseline value
was also removed from theSAAdata set that was 5 SDs greater than
the mean. The trials were identical in design and involved twice-
daily intakeof thenutrient bar.Characteristics of the study cohort
are shown in Table 2. Exclusion criteria were intercurrent in-
fectious disease, untreated stage II hypertension, andmedication
for diabetes or dyslipidemia. Clinical trials were approved by the
institutional review board of Children’s Hospital and Research
Center Oakland. All participants signed informed consent forms
prior to enrollment.
(continued from previous page)
hsCRP, high-sensitivity C-reactive protein; IDL, intermediate-
density lipoprotein; OW/OB, overweight/obese; PPAR, peroxi-
some proliferator-activated receptor; RCT, reverse cholesterol
transport; SAA, serum amyloid A; TC, total cholesterol; TG,
triglyceride; V/M, vitamins and minerals
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Intervention
The study design was an open label, nonrandomized 8 wk clinical
trial in which participants acted as their own control subjects.
Participants were advised to discontinue all vitamin,mineral, and
fiber supplements and any other nutraceuticals 2 wk before the
initiationof each trial. Compliancewith these guidelines aswell as
absence of intercurrent infectious disease was assessed by self-
report. Consumption of 2 bars each day was advised, with the first
tobeeatenbeforenoonand thesecond ineither theafternoonor
evening. Participants were advised to drink a minimum of 8
ounces of water with each bar. No guidelines as to whether to use
the bar as a meal replacement or a supplement were given.
Baseline, 2 and 8 wk visits to the clinical research center in-
cludedmeasurements of height, weight, andwaist circumference
taken at the umbilicus. Compliance with bar consumption
averaged 95%, as assessed by questionnaire at each visit to the
clinical research center. Each physical measurement was taken
twice and averaged. BP and heart rate (HR; Dinamap, GE
Healthcare, Wauwatosa, WI, USA) were assessed in triplicate and
averaged. Fasting venous blood samples were taken in EDTA-
containing tubes and immediately processed.
Biochemical analyses
Lipid profiles
Plasma samples preparedwithin 15min of collectionwere kept at
4°C throughoutprocessing.For 1of the3 trials analyzed, thebasic
lipid panel [total cholesterol (TC), triglycerides (TGs), HDL-c,
and LDL cholesterol (LDL-c)] was determined as follows. Plasma
TC and TG concentrations were determined by enzymatic
TABLE 1. Composition of bars
Bar components Bar 1 Bar 2 Bar 3
Total calories (kcal) 107 124 107
Total fat (g) 5.04 5.09 5.04
Saturated fat (g) 2.52 2.54 2.52
Trans fat (g) 0.0 0.0 0.0
Cholesterol (mg) 0.0 0.0 0.0
DHA, 22:6 n-3 (mg) 200 200 200
Sodium (mg) 2.71 3.002 2.71
Potassium (mg) 142 158 142
Total carbohydrate (g) 19.7 25.4 19.7
Fiber, total dietary (g) 7.31 8.79 7.31
Sugars (g) 7.58 11.0 7.58
Total protein (g) 3.78 3.91 3.78
Vitamin A (retinol activity
equivalents)
71.9 35.6 71.9
b-Carotene (mg) 201 180 201
Calcium (mg) 287 362 287
Vitamin D3 (IU) 0.0 2300 200
Vitamin K1 (mg) 45 36 45
Riboflavin (mg) 0.63 0.65 0.63
Vitamin B6 (mg) 0.69 0.71 0.69
Vitamin B12 (mg) 0.80 0.80 0.80
Pantothenic acid (mg) 1.39 1.35 1.39
Zinc (mg) 2.8 2.84 2.8
Copper (mg) 283 287 283
Chromium (mg) 33 33 33
Vitamin C (mg) 105 106 105
Iron (mg) 1.89 1.98 1.89
Vitamin E (a, g tocopherols) (mg) 6.63 6.70 6.63
Thiamine (vitamin B1) (mg) 0.43 0.44 0.43
Niacin (mg) 7.77 7.90 7.77
Folate (mg) 316 558 316
Biotin (mg) 7.5 7.5 7.5
Phosphorus (mg) 42.2 45.1 42.2
Magnesium (mg) 179 180 179
Selenium (mg) 6.24 6.20 6.24
Manganese (mg) 0.36 0.36 0.36
Choline (mg) 127 128 127
Glutamine (g) 1.0 1.0 1.0
Lactate (mg) 0.0 326 0.0
Glycerine (g) 1.00 1.50 1.00
Total polyphenols (mg) 473 515 473
Monomeric polyphenols (mg) 87.8 157 87.8
Values are amounts contained in 1 bar; dosage is 2 bars per day. Values were calculated from U.S.
Department of Agriculture (USDA) tables (58) and individually added nutrients. Fruit concentrate
polyphenol concentrations are derived from the USDA Database for the Flavonoid Content of Selected
Foods, Release 2.1 (59). The Nutrient Database numbers are 09050, 09078, 97074, and 09279. Polyphenol
content of blueberry powder was provided by the Highbush Blueberry Council. The patent is pending (26).
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procedures on an Express 550 Plus analyzer (Ciba Corning,
Oberlin, OH, USA) controlled by the U.S. Centers for Disease
Control and Prevention-U.S. National Institutes of Health
National Heart, Lung, and Blood Institute standardization mon-
itoring program. HDL-c was measured after dextran sulfate
precipitation of plasma. LDL-c was calculated using a standard
formula(61) for all sampleswithTGconcentrations,400mg/dl.
For the other 2 trials analyzed, the basic lipid panel (TC, TGs,
HDL-c, and LDL-c) was determined by a commercial provider
(ARUP Laboratories, Salt Lake City, UT, USA). Ion mobility
TABLE 2. Baseline metabolic and anthropometric characteristics of OW/OB and lean participants
Characteristics BMI ,25 BMI $25
Mean clinical measures (SD) (n = 29) (n = 30)
Age (years)* 43.4 (14.3) 52.7 (12.6)
Female sex (%)a 86.7 40
Physical
BMI* 22.6 (1.7) 29.7 (3.4)
Weight (kg)* 62.3 (8.4) 92.0 (16.8)
Waist circumference (cm)* 80.5 (6.5) 104.0 (11.5)
Systolic BP (mmHg)* 112.2 (11.0) 120.8 (9.7)
Diastolic BP (mmHg)* 70.7 (7.5) 77.8 (8.3)
HR (bpm) 64.7 (11.9) 67.0 (6.9)
Lipids
HDL-c (mg/dl)* 68.7 (20.8) 49.8 (12.5)
LDL-c (mg/dl)† 101.3 (34.0) 124.4 (36.6)
TC (mg/dl) 186.1 (35.6) 201.9 (36.6)
Non-HDL-c (mg/dl)* 115.0 (37.9) 149.2 (36.6)
TGs (mg/dl)* 80.7 (41.2) 157.4 (118.9)
VLDL-c (mg/dl)* 16.1 (8.2) 31.5 (23.8)
TG/HDL-c* 1.4 (1.2) 3.9 (4.7)
Insulin resistance
Glucose (mg/dl)* 93.3 (7.7) 102.8 (7.5)
Insulin (mU/L)* 6.4 (3.9) 13.3 (6.9)
HOMA-IR* 1.4 (0.8) 3.4 (1.7)
Inflammation related
hsCRP(mg/L)* 0.87 (1.3) 2.1 (1.6)
Adiponectin (ng/ml)* 6797 (5895) 3179 (2858)
SAA (ng/ml) 918.4 (667.7) 3887 (8526)
Mean lipoprotein particle measurements (SD) (n = 28) (n = 30)
HDL particles
HDL-2b (nM)* 3187 (1959) 1467 (967.1)
HDL3_2a (nM) 5548 (1788) 5686 (1391)
Total (nM)† 8736 (2704) 7152 (1747)
LDL particles
Peak diameter (A˚)* 224.7 (6.1) 219.8 (6.2)
LDL I (nM) 346.3 (128.3) 346.0 (145.6)
LDL IIa (nM)† 210.0 (98.1) 267.2 (92.4)
LDL IIb (nM)* 205.2 (103.1) 297.2 (110.9)
LDL IIIa (nM)† 147.7 (121.3) 248.2 (172.0)
LDL IIIb (nM) 52.5 (48.0) 88.4 (82.7)
LDL IVa (nM) 57.3 (30.9) 76.0 (48.1)
LDL IVb (nM) 52.6 (23.3) 65.9 (26.9)
LDL IVc (nM) 32.8 (10.2) 37.0 (15.1)
Total (nM)* 1105 (354.4) 1426 (313.8)
VLDL and IDL particles
IDL I (nM) 170.8 (65.3) 188.3 (58.5)
IDL II (nM)† 277.7 (131.7) 204.8 (76.4)
VLDL small (nM) 72.7 (31.9) 72.7 (24.6)
VLDL intermediate (nM)* 49.6 (26.6) 65.8 (24.1)
VLDL large (nM)* 15.0 (12.3) 25.7 (14.5)
n refers to the number of observations measured, not the number of participants (see Materials
and Methods). The number of observations averaged for each measure is indicated at the head of each
column unless otherwise indicated. BMI ,25: n = 23 (non-HDL), n = 27 (adiponectin), and n = 5 (SAA).
BMI $25: n = 28 (LDL-c), n = 22 (non-HDL), n = 30 (adiponectin), and n = 18 (SAA). The differences in
this table are not intended to represent a definitive comparison because the lean and OW/OB groups
were not matched for age, sex, or ethnicity, which are known to affect the metabolic profile. Ethnicities
were BMI ,25 (48% Caucasian, 31% Asian-American, 7% Hispanic, 7% unknown, 3% African American,
and 3% other) and BMI $25 (58% Caucasian, 10% Asian-American, 16% Hispanic, 10% unknown, and
6% African American). HDL3_2a, small HDL (7.6–10.5 nm). For HDL, LDL, and other particle
definitions, see Abbreviations. aNo significant difference by x2 analysis. *P , 0.01; †P , 0.05.
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analysis was used to measure concentrations of lipoprotein sub-
fractions in all 3 trials, as previously described (62).
Other measures
Plasma fasting glucose, insulin, and hsCRP were measured using
standard procedures by a commercial provider (ARUP Labora-
tories). Insulin resistance was estimated using the homeostatic
model of insulin resistance (HOMA-IR) calculated as fasting
glucose(milligramsperdeciliter)3 fasting insulin(milli-international
units per liter) 4 405. High molecular weight adiponectin was
measured by solid-phase sandwich ELISA (Quantikine; R&D
Systems, Minneapolis, MN, USA). SAA was measured using de-
tection antibodies that emit light upon electrochemical stimula-
tion (Meso Scale Discovery, Rockville, MD, USA).
Statistical analysis
Prior to pooling data from the 3 trials, quantitative measures and
changes frombaseline to2and8wkwereassessedbyANOVAwithin
each trial. Outcome distributions were similar in all 3 trials, and
results were pooled. All statistical analyses were performed using
SAS (version 9.3; SAS Institute, Cary, NC, USA). Variables included
standard clinical metabolic and anthropometric measures and li-
poprotein subfraction concentrations. Means6 SE were calculated
for the various subgroups and time points. Correlations were com-
puted using Spearman’s nonparametric estimates. Data were ex-
amined for assumptions of normality using measures of skewness
and kurtosis, plots, and the Anderson-Darling test. Log trans-
formations were performed for highly skewed data (HOMA-IR, in-
sulin, hsCRP, TGs, SAA, and adiponectin). Initial bivariate analysis
using Student’s t test was conducted to compare baseline values
between lean and OW/OB. Linear regression models were con-
structed on the continuous outcomes and on changes from base-
line.Bar-inducedchangeswereexaminedover time in theOW/OB
and in the 2 OW/OB subgroups using general linear models with
time treated as repeated measures. The generalized estimating
equation approach, with an exchangeable working correlation
structure, was used to account for the within-person correlation in
outcomes at different time points (i.e., statistical analysis included
adjustment for participants who were in .1 trial). A significance
level of 0.05 was used for all statistical tests. Because multiple statis-
tical tests were conducted, some false positives may have occurred.
RESULTS
Baseline characteristics of lean and OW/OB
participants
Baseline metabolic characteristics of lean and OW/OB
participants are shown in Table 2 and reflect recognized
differences between these groups (63–68). As shown,
HDL-c is significantly lower in theOW/OB, andBP,LDL-c,
TGs, insulin resistance (as measured by HOMA-IR), in-
sulin, glucose, and inflammation (as measured by hsCRP)
are all significantly higher. Adiponectin and SAA also re-
flect known differences between the OW/OB and lean.
Adiponectin is significantly higher in the lean (55, 69), and
SAA is higher in the OW/OB (70).
Significant lipoprotein subfraction differences between
theOW/OBand lean groups are 1)higher concentrations
of HDL-2b and intermediate-density lipoprotein (IDL) II
in the lean, 2) greater LDL peak diameter in the lean, and
3) lower concentrations of LDL IIb and large VLDL (very
LDL) in the lean. In addition, as expected (71), across all
OW/OB and lean participants, concentrations of small
LDL subfractions are strongly and positively correlated
with TG concentration and strongly and negatively corre-
latedwithHDL-c. The correlation coefficient of the sumof
the 2 most atherogenic small subfractions (LDL IIb and
IIIa) (72) withHDL-c is20.74 (P, 0.001; n = 60) and with
TGs is +0.71 (P, 0.001; n = 60).
Effects of 2 and 8 wk twice-daily consumption of 2
nutrient bars in lean and OW/OB healthy adults
Effects of nutrient bar consumption in the lean
Previously, we reported that consumption of 2 nutrient
bars a day for 2 wk by healthy, predominantly lean [body
mass index (BMI) ,25] or slightly overweight adults sig-
nificantly increased HDL-c, particularly the HDL-2b [also
knownas (aka)HDL-L] (51). Similar resultswereobserved
at 2 wk for lean participants in this study and persisted at
8 wk, as shown in Fig. 1. HDL-c increased in 76% of partic-
ipants, with an overall average increase of 4.16 1.0 mg/dl
(P,0.001),andHDL-2bincreased4926148nM(P,0.007).
The additional major change observed in this study was
a large increase in the adipokine adiponectin, not mea-
sured in our earlier study (51), which also increased very
significantly at 2 wk (+10266 405 ng/ml; P, 0.002) and
8 wk (+1475 ng/ml; P = 0.005).
Additional parameters for which changes were statis-
tically significant at 8 wk included total HDL subfrac-
tions (HDLPs) (+859 6 296 nM; P = 0.0040) and TC
(+9.5 6 3.2 mg/dl; P = 0.0029), not unexpected given
the robust increases in HDL measures, and several
other statistically significant changes: non-HDL choles-
terol (+6.6 6 3.1 mg/dl; P = 0.044), waist circumference
(+1.16 0.6 cm; P = 0.042), and LDL IIa (+20.46 9.2 nM;
P = 0.047). There were no statistically significant changes
Figure 1. Effects of the nutrient bar in the lean (BMI ,25)
after 2 and 8 wk consumption of 2 nutrient bars each day.
Chol., cholesterol; Circum., circumference. Values plotted are
changes from baseline, averaged across all participants and
plotted as percentage of the overall baseline mean for each
endpoint. Average changes and SE are specified below the
figure. HDL-2b is one of the 2 classes of HDL subfractions
identified by the lipid particle-sizing assay and is defined in
Abbreviations. *P , 0.05; **P , 0.01; tP , 0.10.
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in any other biochemical or anthropometric measures at
8 wk in the lean group (data not shown).
Effects in the OW/OB
Bar-induced changes after 2 and 8 wk in the OW/OB are
shown for metabolic (Fig. 2A) and anthropometric (Fig.
2B)measures and in Fig. 3 for lipid subfractions. As shown,
after 8 wk consumption of 2 bars a day, statistically signifi-
cant (P, 0.05) or trending significant (P, 0.10) changes
in the direction of baseline values typical of the lean
(Table 2) were observed: HDL-c (+2.4 6 1.2 mg/dl;
P = 0.078); TGs (234.3 6 21.0 mg/dl; P = 0.061); insulin
resistance (as measured by HOMA-IR, 20.60 6 0.2;
P = 0.011); insulin (22.3 6 0.90 mU/L; P = 0.0088);
glucose (22.2 6 1.2 mg/dl; P = 0.054); and adiponectin
(+7436431ng/ml;P = 0.079) (Fig. 2A). Changes inhsCRP
(20.306 0.22 mg/L) and SAA (22046 236 ng/ml) were
also in the direction of improvement. Improvements in
anthropometric measures were also observed, as shown in
Fig. 2B: diastolic bloodpressure (DBP) (22.461.3mmHg;
P = 0.082); HR [23.7 6 1.0 beats per minute (bpm);
P, 0.001]; weight (20.806 0.40 kg; P = 0.039); and waist
circumference (21.80 6 0.90 cm; P = 0.043).
Changes in lipid subfractions are shown in Fig. 3.
Changes in HDL subfractions (HDL-2b and HDL3_2a)
indicate thatnutrientbar-induced increase inHDL-c in the
OW/OBisprimarily due toan increase in theHDL-2b(aka
HDL-L), as reported previously in predominantly lean
individuals (51).
Little change in LDL-c is apparent in Fig. 2A. However,
examination of Fig. 3 suggests consistent favorable
decreases across themore atherogenic (72) small LDL
subfractions (LDL IVa, IVb, and IVc and LDL IIIa and
IIIb) and consistent favorable increases in the less ath-
erogenic (72) larger subfractions (LDL I and IIa and
IDL 2). Only increases in 2 large subfractions [LDL I
(+40.86 18.1 nM) and IDL 2 (+20.76 10.5 nM)] reached
statistical significance, and decreases in only 2 small
subfractions trendedsignificant[LDLIIIb(221.7612.4nM;
P = 0.069) and IIIa (244.06 24.7 nM;P = 0.077)].However,
the consistency of downward movement in the small
dense subfractions and upwardmovement in the larger
subfractions is persuasive.
In summary, consumption of 2 bars each day for
2 months resulted in positive changes in indicators of car-
diovascular health (HDL and LDLdyslipidemia, DBP, and
HR), insulin resistance (HOMA-IR, insulin, and glucose),
and obesity itself (weight and waist circumference). The
significant increase in adiponectin is also consistent
with improved metabolic health (55, 69, 73). There were
no gastrointestinal or other adverse effects from bar
consumption.
Inflammation blunts responsiveness to
bar consumption
In the OW/OB, baseline inflammation (hsCRP) is inversely
correlated with early (2-wk) increase in all 4 HDL measures
and with later (8-wk) increase in less atherogenic LDL and
IDL lipid subfractions
As shown, baseline hsCRP in the OW/OB is inversely
correlated with bar-induced change from 0–2 wk (but not
0–8 wk) in all measures of HDL: HDL-c (r = 20.42;
P = 0.025); HDL3_2a (r = 20.47; P = 0.010); HDL-2b
(r =20.44; P = 0.018); andHDLP (r =20.55; P = 0.0021)
(Fig. 4A–D). Baseline hsCRP was also inversely correlated
withbar-induced0–8wk (butnot 0–2wk) change in the less
atherogenic LDL subfractions LDL I (r =20.52;P = 0.0044)
and IDL2 (r =20.46; P = 0.015).No additional correlations
were observed.
In the OW/OB, improvement in almost all measures occurs
more robustly in those who are less inflamed at baseline
Baseline hsCRP values in OW/OB participants are il-
lustrated in Fig. 5. As shown, approximately half of the
Figure 2. Improvements of measures linked to cardiovascular risk, insulin resistance, inflammation, and obesity in the OW/OB.
A) Metabolic. B) Anthropometric. Results after consumption of 2 nutrient bars per day for 2 and 8 wk are shown. *P , 0.05,
**P , 0.01, tP , 0.10. See Fig. 1 legend for additional information.
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baseline hsCRP values fall below an informal cutoff of 1.5,
which has been used to classify chronic inflammation
linked to CVD risk (74).
In Figs. 6, 7, and 8, effects of nutrient bar consumption
for 2 and 8 wk are shown for each of these 2 inflammation
subgroups for basic clinical measures (Figs. 6 and 7) and
lipoprotein subfractions (Fig. 8). All measures with
changes that were either statistically significant or trended
significant in either the lower- or higher-inflammation
subgroup are plotted. As shown in Figs. 6A and 7A, with the
exception of adiponectin, nutrient bar-induced change in
the less inflamed subgroup is clearly more robust com-
pared to the more highly inflamed subgroup. As shown in
Figs. 6B and 7B, change in the anthropometricmeasures is
also more robust in the less inflamed subgroup, with the
exception of decreased HR. In Fig. 8, a similar pattern is
seen for the lipid subfractions. HDL-2b increases in both
subgroups, but the response is slower in themore inflamed
subgroup. The suggestive realignment of less and more
atherogenic LDL and IDL subfractions toward a healthier
Figure 3. Improvements of lipo-
protein subfractions in the
OW/OB. HDL, LDL, IDL, and
VLDL subfractions are as defined
in Abbreviations. intermed., inter-
mediate. *P , 0.05, **P , 0.01,
tP , 0.10. See Fig. 1 legend for
additional information.
Figure 4. Spearman correlations in the OW/OB between baseline hsCRP and change after consumption of 2 nutrient bars each
day for 2 wk [(A) HDL-c (milligrams per deciliter), (B) HDL-2b (nanomolar), (C) HDL3_2a (nanomolar), and (D) HDLP
(nanomolar)] or change after 8 wk [(E) LDL I (nanomolar), and (F) IDL 2 (nanomolar)]. Correlation coefficients and P values
were r = 20.42 and P = 0.025 (HDL-c), r = 20.44 and P = 20.018 (HDL-2b), r = 20.47 and P = 0.010 (HDL3_2a), r = 20.55 and
P = 0.0021 (HDLP), r = 20.52 and P = 0.0044 (LDL I), and r = 20.46 and P = 0.015 (IDL 2).
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profile after 8 wk of nutrient bar consumption, as observed
in the OW/OB group as a whole (Fig. 3), is now clearly
shown to be due to bar-induced changes in the less-
inflamed subgroup.
Most of the nonsignificant decrease in hsCRP in the
OW/OB group (Fig. 2A) occurred in the higher-
inflamed subgroup; decrease at 8 wk was statistically
significant (20.78 6 0.37 mg/L; P = 0.03). Changes in
SAA were not significant.
DISCUSSION
A nutrient-dense, high-fiber, fruit-based, low-calorie bar
intended to restore nutrient adequacy by filling gaps in
Western diets was used as a dietary intervention in three
2-month clinical trials in lean and OW/OB healthy adults
to examine effects of consuming 2 bars a day onmetabolic
and anthropometric measures. Metabolic improvements
were seen in both lean and OW/OB participants. Striking
improvements occurred in the OW/OB (Figs. 2 and 3),
primarily inparticipantswith relatively low levels of chronic
inflammation (Figs. 4, 5, 6, 7, and 8). These improve-
ments were in major areas that characterize metabolic
dysregulation associated with obesity: HDL and LDL dys-
lipidemia, as well as other indicators of cardiovascular
health (HR and DBP) and insulin resistance (HOMA-IR).
Statistically significant improvements inweight andwaist
circumference also occurred primarily in the OW/OB
group with lower levels of chronic inflammation (Figs. 2B
and 6B). These reductions were small, not unexpected
given the relatively short duration of the intervention and
the fact that;220daily kilocalorieswere added in the form
of the nutrition bar without requirements to adjust base-
line diet or otherwise change behavior.
This is the first report of which we are aware that docu-
ments the resistance of OW/OB individuals with higher
levels of chronic inflammation to dietary-induced im-
provements in a wide range of metabolic and anthropo-
metric indicators of obesity-associated dysregulation. The
adverse effect of chronic inflammation on diet-induced
improvements in some lipids was previously observed
(75–79), and one study reported that baseline plasma IL-6
concentrations were significantly higher in individuals
more resistant to weight loss (80).
It is of interest that bar-induced improvements at 8 wk in
HDL-2b and the adipokine adiponectin appeared to be
relatively independent of inflammation, occurring in the
Figure 5. Distribution of baseline hsCRP values
among OW/OB participants. Each of the 30
observations in the OW/OB is plotted as
baseline hsCRP (milligrams per liter). All parti-
cipants with baseline hsCRP values ,1.5 mg/L
were classified as less inflamed, and those with
baseline values .1.5 mg/L were classified as
more inflamed.
Figure 6. Changes in the lower-
inflammation OW/OB subgroup
after 2 and 8 wk consumption of
the nutrient bar. A) Metabolic.
B) Anthropometric. Parameters
plotted were selected from those
with changes that were statistically
significant or trending signifi-
cant in either of the 2 inflam-
mation subgroups over the 8-wk
period. Additional significant
or trending significant changes
not plotted are as follows. BMI:
0–8 = 20.25, P = 0.086; TC:
0–8 = 24.93 mg/dl, P = 0.079;
TG/HDL-c: 0–8 =21.35, P = 0.046;
and non-HDL cholesterol:
0–8 = 27.10 mg/dl, P = 0.062.
*P , 0.05, **P , 0.01, tP , 0.10.
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lean (Fig. 1), in the OW/OB as a whole (Figs. 2A and 3),
and in both OW/OB inflammation subgroups (Figs. 6A,
7A, and 8). Higher plasma concentrations of adiponectin
have been suggested as an overall biomarker of metabolic
health (73) and have been linked to increased HDL-c and
decreased inflammation (55, 81). Adiponectin was repor-
ted to induce RCT (82, 83), which could help to explain
the bar-induced increase in HDL-2b (54) observed here
and previously (51).
Effects of the nutrient bar on inflammation
Inflammatory response is a recognized mechanism in the
pathogenesis of atherosclerosis and related risk for CVD
(18). Among severalmeasures of inflammation (including
SAA), hsCRP is preferentially recommended for clinical
use in identifying individuals at risk (18). In the OW/OB,
both hsCRP and SAA appeared to decrease after bar con-
sumption, but results did not reach statistical significance
(Fig. 2A). However, there was a statistically significant re-
duction in hsCRP (;20%; P = 0.030) among participants
who fell into CVD risk categories considered to be high
average or high (Fig. 5) (18). Although a causal role of the
nutrient bar in improving inflammationcannot be inferred
from these results, it is suggested that the initial effect of the
bar in the more inflamed OW/OB subgroup may be to
decrease inflammation, which would then allow positive
changes in metabolic dysregulation to manifest over a lon-
ger period than the 8-wk duration of this intervention. In
this regard, it is noted that HDL-2b increased after 2 wks of
bar consumption in the lower-inflammation groups (lean,
Fig. 1; lower-inflammationOW/OBsubgroup, Fig. 8A), but
not until 8 wk in the higher-inflammation OW/OB sub-
group (Fig. 8B).
Possible mechanisms
It is suggested that improvements in such a wide range of
metabolic and anthropometric measures in the OW/OB
(Figs. 2, 3, 6, and 8) may be the result of the restoration
of impaired underlying metabolic processes due to the
resupply by the nutrient bar of critical dietary components
Figure 7. Changes in the
higher-inflammation OW/OB
subgroup after 2 and 8 wk con-
sumption of the nutrient bar.
(A) Metabolic and (B) anthro-
pometric measures. Parameters
plotted were selected from those
with changes that were statistically
significant or trending significant
in either of the 2 inflammation
subgroups over the 8-wk period.
The only additional change not
plotted was non-HDL cholesterol:
0–8 = +6.8 mg/dl; P = 0.075.
**P , 0.01, tP , 0.10.
Figure 8. Changes in the lower- and higher-inflammation OW/OB subgroups after 2- and 8-wk consumption of the nutrient bar.
A) Lower-inflammation subgroup. B) Higher-inflammation subgroup. Lipid particle subfractions are shown. Parameters plotted
were those with statistically significant or trending significant changes in either of the 2 subgroups over the 8-wk period. Int.,
intermediate; Lg., large; Diam., diameter. *P , 0.05, **P , 0.01, tP , 0.10.
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deficient in Western diets. Mitochondrial stress and
impaired gut wall integrity are candidate underlying pro-
cesses that may be improved by bar consumption. Both of
these conditions are common in the obese (84, 85), and
both are linked to poor diets (86, 87) and to insulin re-
sistanceand inflammation(88, 89).Bar-inducedreduction
of mitochondrial stress and improved gut integrity would
be expected to have multiple beneficial consequences
similar to the metabolic improvements observed in this
study. The restoration of an internal metabolic environ-
ment that manifests a leaner metabolic profile would also
allow the metabolic flexibility required for weight loss and
clearance of ectopic adiposity (90, 91).
Mitochondrial stress
The metabolic efficiency of mitochondria in converting
fuel (carbohydrates, lipids, and amino acids) to ATP
decreases in the obese relative to the lean (92). The gen-
eration of oxidants is a consequence of the accumulation
of NADH over NAD+, which occurs due to chronic hyper-
glycemia resulting from overnutrition (93–95). Oxidants
directly interfere with insulin-signaling efficiency (96–98),
and oxidant-initiated oxidative damage triggers inflam-
mation because cells that sustained such injury are cleared
by immune cells (98). Fatty acid accumulation resulting
from decreased mitochondrial efficiency also inhibits
insulin-signaling efficiency (99, 100).
There are several ingredients in the nutrient bar that
may positively impact mitochondrial stress. High-viscosity
dietary fiber HPMC has been shown to slow glucose ab-
sorption (101) and to preserve respiratory quotients in rats
consuming a high-fat diet (102). Furthermore, 2 nutrient
bars (thedaily dose) also contain 400mgdocosahexaenoic
acid (DHA), a known peroxisome proliferator-activated
receptor (PPAR)-a agonist. Activation of the PPAR path-
way leads to increased fatty acid oxidation and preferen-
tially reduces small proatherogenic LDL subfractions
(103). The bar also contains high concentrations of poly-
phenolic compounds from fruit and dark chocolate.
Polyphenolic consumption in healthy overweight individ-
uals has been shown to increase resting energy expendi-
ture, which would relieve mitochondrial reductive stress
described above (104). Polyphenols also increase cellular
antioxidant defense by activating Nrf2 phase-2 detoxi-
fication pathways that antagonize inflammation (105).
Gut wall integrity
Gut wall integrity and the intestinal microbiome are im-
paired by high-fat and high-sugar diets commonly con-
sumed by the obese (106–108). Evidence points to the
importance of fiber, its metabolites, and other dietary
components (106, 109–111) in maintaining a healthy gut
barrier (112, 113) and intestinal microbiome (114) to
prevent diet-induced chronic inflammation and insulin
resistance (84, 106, 115). The consequence of poor nutri-
tion is a condition termed “leaky gut,” in which fragments
of gram-negative bacteria (LPS aka endotoxin) pass
through the gut into systemic circulation, leading to
chronic inflammation (106, 116, 117). The nutrient bar
may help to strengthen the gut barrier epithelium through
provision of nutrients that support the gut’s bioenergetic
capacity and thus its resiliency to intestinal permeability
(118). These nutrients include soluble fiber and its fer-
mentation products (26, 51) such as short-chain fatty acids
(41, 42), glutamine (43–45), and zinc (119–121). Suchbar-
induced strengthening of the gut epithelium, and conse-
quent reduction in plasma endotoxin, should be possible
within the first 2 wk of bar consumption (122), compatible
with the observed early (2 wk) rise in HDL-2b and adipo-
nectin. Decreasing endotoxin entry by strengthening the
gut wall would result in a reduction in inflammation
(106, 123) and the consequent endocrine (i.e., insulin and
leptin) (124, 125) and mitochondrial stress responses to
inflammation that make it difficult to lose excess fat and
maintain a healthy body weight.
Summary
It is suggested that the less inflamed OW/OB subgroup is
lessmetabolically impaired and thus better poised tomove
toward a leaner metabolic profile in response to improved
function resulting from nutrients supplied by the bar.
The higher-inflammation subgroup must first reduce in-
flammation. It is posited that reductions in hsCRP (Fig. 2),
most of which occurred in the higher-inflammation sub-
group, may reflect what is potentially the first step toward
a leaner metabolic profile, which may require a longer
period todevelop inmorechronically inflamed individuals
than the 8-wk period of the trials analyzed in this report.
Practical implications for weight
management programs
Conventional weight management strategies can be suc-
cessful [e.g., (126–128)], but results are often disappoint-
ing (24, 25). Poor weight loss and maintenance of weight
loss are, in part, due to the incompletely understood ob-
servation that some people lose weight more easily than
others, independent of compliance (23, 25, 129, 130).
Results presented here suggest that OW/OB individuals
who respond poorly to a weight loss programmay be those
that have higher baseline chronic inflammation. Such
individuals may require a longer, or different, approach
than those that are less inflamed.
Poor compliance is alsoamajorcauseof lowsuccess rates
inweight lossmanagementprograms (24, 131, 132).This is
not surprising because these programs typically require
dietary andactivitymodifications that aredifficult formany
to initiate and sustain. It is suggested that weight manage-
ment programs will be more successful if interventions,
such as that employed here, are used as a first step to help
participants transition to healthier eating and lifestyle
habits. In this study, participants were not instructed to
make any lifestyle changes other than to eat 2 nutrient bars
each day. This study design imposed relatively minor
restrictions on participants, and compliance was very high
(95%). The modest but statistically significant loss in
weight (1.16 0.5 kg; P = 0.0051) and waist circumference
(3.16 1.4 cm; P = 0.019) that occurred in the less inflamed
OW/OB subgroup may have been the result of bar-
induced improvement in metabolic health that enabled
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the metabolic flexibility required to initiate weight loss.
Early success in weight management programs may en-
courage participants toward higher compliance through-
out the program, and early identification of participants
whose metabolism is resistant to change should also be
beneficial.
Potential for use of natural food-based nutrient
mixtures as alternatives or companions to drugs used
to treat obesity-associated metabolic dysregulation
Obesity-associatedmetabolic dysregulation is often treated
with drugs: dyslipidemia with statins and fibrates (133,
134), insulin resistance with thiazolidinediones and met-
formin (135, 136), and chronic inflammation with non-
steroidal anti-inflammatory drugs (137). All of these drugs
have demonstrated clinical benefits. However, because
most drugs act by pharmacologically blocking or acceler-
ating cellular pathways, pleiotropic, often poorly un-
derstood and sometimes negative side effects can result
(134, 138, 139). On the other hand, food-based nutrient
mixtures, such as the nutrient bar used here, that contain
nutrients at normal dietary concentrations are not expec-
ted to have significant negative side effects. The full po-
tential of such food-based nutrientmixtures as alternatives
or companions to drugs for treatment of metabolic dysre-
gulation associated with obesity has not been given ade-
quate attention.
Limitations
The clinical trial design used in this and previous (51)
nutrient bar trials did not include a placebo control
group; instead, participants acted as their own controls.
Difficulties in applying the same placebo standards used
for drug trials to nutritional interventions have been
widely discussed [e.g., (140)]. In addition, dietary intake
during the trial was not monitored. Thus, it is not known
whether participants altered their food choices or con-
sumed fewer calories during the trials. If such changes
occurred, they could have contributed to the positive
effects observed.
CONCLUSIONS
The broad-spectrum metabolic and anthropometric im-
provements observed after 2 months of twice-daily con-
sumption of a low-calorie food-based nutrient bar aimed at
filling gaps in poor diets suggest that it is not necessary to
impose severe changes in diet and lifestyle patterns to be-
gin to effect positive changes in the OW/OB, and also in
the lean. Two-month consumption of the nutrient bar did
not make the OW/OB lean or completely correct un-
healthy metabolism, but it did begin a process of favorable
metabolic change. The fact that almost all statistically
significant favorable changes occurred in the subgroup
of the OW/OB with less chronic inflammation suggests
an explanation for why some OW/OB have difficulty
losing weight. This study highlights the power of food-
based, targeted, dietary interventions as alternatives or
adjuncts to the use of drugs to treat obesity and associated
metabolic dysregulation.
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